Skip to content
Sign in
StableHealthReported 2026-11-19 21:01

Johnson & Johnson submits sNDA to FDA for CAPLYTA in bipolar mania

Johnson & Johnson filed a supplemental New Drug Application with the U.S. FDA seeking approval of CAPLYTA (lumateperone) for the treatment of manic or mixed episodes associated with bipolar I disorder in adults, based on two positive Phase 3 studies showing rapid symptom improvement.

In depthRead the in-depth story

Why it matters. If approved, CAPLYTA would become the fifth approved indication for the drug, expanding its use in a severe psychiatric condition affecting an estimated 11 million U.S. adults and adding a new treatment option for acute mania.

01

Who and what it touches

Janssen Biotech, Inc.part ofHalda Therapeuticsacquiresmanufacturing campusinvests inChinaprice exposurehealthcareoperates inHealth care cost cont…cost exposureMiddle Eastgeographic exposureregulatory approvalregulatory exposureJohnson & Johns…

Into Johnson & Johnson

From Johnson & Johnson

Each line is a relation with evidence behind it, drawn in the direction it points. A line shows that two things are connected, not how far this change reaches.

02

Evidence

  • PPR Newswire news releasesCompany2026-11-19 21:01
    Studies 451 and 452 are two positive randomized, double-blind, placebo-controlled Phase 3 studies of lumateperone versus placebo in adults with manic episodes, with or without mixed features, associated with bipolar I disorder.
    View source